Brokerage : Mirae Asset Securities
Analyst : Seung-min Kim
Investment Rating : BUY (Maintained)
Target Price : KRW 280,000 (Raised)
Core Momentum : Earnings estimate upgrades driven by stronger-than-expected profitability contributions from new biosimilars and favorable valuation vs global peers supported by in-house cost efficiency
📊 1. [Valuation & Key Financial Metrics]
- Rating and Target Price: BUY (Maintained), Target Price raised to KRW 280,000 (from KRW 260,000) by applying a Target EV/EBITDA of 28x to 12-month forward EBITDA of KRW 2.29T, offering 56.7% upside potential against the base share price of KRW 178,700 (as of 26.07.27).
- Consolidated Financial Summary & Forecasts (K-IFRS):
- 2024A: Revenue KRW 3,557B, Operating Profit KRW 492B (OPM 13.8%), Net Profit (Controlling) KRW 423B, EPS KRW 1,703, P/E 101.1x, P/B 2.2x, ROE 2.5%
- 2025A: Revenue KRW 4,162B, Operating Profit KRW 1,168B (OPM 28.1%), Net Profit (Controlling) KRW 1,030B, EPS KRW 4,238, P/E 40.7x, P/B 2.2x, ROE 5.9%
- 2026F: Revenue KRW 5,387B, Operating Profit KRW 1,776B (Consensus KRW 1,784B, OPM 33.0%), Net Profit (Controlling) KRW 1,592B, EPS KRW 6,775 (+59.9% YoY), P/E 26.4x, P/B 2.0x, ROE 8.9%
- 2027F: Revenue KRW 5,988B, Operating Profit KRW 2,055B (OPM 34.3%), Net Profit (Controlling) KRW 1,733B, EPS KRW 7,452, P/E 24.0x, P/B 1.9x, ROE 8.9%
- 2028F: Revenue KRW 6,587B, Operating Profit KRW 2,391B (OPM 36.3%), Net Profit (Controlling) KRW 2,075B, EPS KRW 8,922, P/E 20.0x, P/B 1.7x, ROE 9.8%
🚀 2. [Market Opportunities & Business Outlook]
- Earnings Upgrades Driven by New Biosimilars: Following 2Q26 earnings outperformance led by the rising revenue share of new biosimilars, annual earnings estimates have been revised upward. The upward revision in profit estimates outpaced revenue as the growth and margin contributions from new biosimilars exceeded initial expectations.
- Comparative Valuation and Business Structure (vs. Sandoz):
- Celltrion trades at ~20x 2026F consensus EV/EBITDA.
- While this appears at a premium to Sandoz’s 14x multiple, Sandoz generates ~65% of revenue from generics (typically valued at <10x) with biosimilars accounting for only ~33%, implying Sandoz’s standalone biosimilar business trades at upper-20x multiples.
- While Sandoz is currently expanding in-house manufacturing from a CMO-dependent model, Celltrion has operated established in-house facilities from inception, securing production efficiency, cost competitiveness, and differentiated profitability.
- Global Biosimilar Market Restructuring:
- The market is consolidating around top-tier players equipped with integrated capabilities across R&D, approval, in-house manufacturing, supply reliability, and direct commercialization (with 3 players across the US, Europe, and Korea forming an oligopoly during 2023–2025).
- Entry attempts by new players targeting patent expiries starting in 2028 are considered signals of structural market growth rather than immediate competitive threats, given uncertainties surrounding rapid ramp-up in quality, capacity, and supply credibility.
📝 Editor’s Comment (Perspective)
The analyst views Celltrion as a top-tier biosimilar player that improves overall profitability through an expanding revenue mix of new biosimilars and maintains cost advantages via its established in-house production system. This perspective emphasizes that, considering differences in business portfolio composition and manufacturing internalization, the company’s valuation remains discounted relative to the standalone biosimilar value of global peers.
To determine whether this investment thesis continues to materialize, key tracking points will be whether the expanding revenue mix of new biosimilars continues to support operating margin expansion, and whether in-house cost competitiveness helps sustain market oligopoly positioning amid future patent expirations from 2028 onward. These variables can be verified through upcoming quarterly earnings releases, official IR materials, and market share disclosures.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
